explore -WSS

explore

author：leisure time 2025-10-01 17:19:37 - browse：39719

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： How one medical school became remarkably diverse

WSS

Trans patients at the end of life deserve respect and dignity

Roche's accidental data boosts hopes for anti

BioMarin wins approval for gene therapy to treat hemophilia A

Trans patients at the end of life deserve respect and dignity

Vivek Ramaswamy made waves in the debate, much as in biotech

Moonlake's readout produced a cash windfall. Risks remain

explore

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

focus

Dobbs anniversary: the lost opportunity of abortion as health care

BioMarin wins approval for gene therapy to treat hemophilia A

Walensky prepares to leave CDC — and Congress — behind

How one medical school became remarkably diverse

Novavax promises a turnaround & Lilly roils the obesity market

FDA advisory panel to debate high blood pressure devices

In age of alternative facts, a scholarly course on calling out crap

As demand for Covid shots wanes, Moderna seeks its next success

How one medical school became remarkably diverse

Study: Spinal cord stimulation helps patients with paralysis walk again

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Former Pear Therapeutics executives start new VC firm

Health officials lay out plans to cope with respiratory virus season

After affirmative action ruling, medical educators look to 'holistic review'

knowledge

focus

leisure time

entertainment